

Resource Summary Report

Generated by [dkNET](#) on Sep 20, 2026

BEAS-2B

RRID:CVCL_0168

Type: Cell Line

Proper Citation

Hysigen Cat# TCH-C132, RRID:CVCL_0168

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0168

Proper Citation: Hysigen Cat# TCH-C132, RRID:CVCL_0168

Description: Cell line BEAS-2B is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Male

Defining Citation: [PMID:2450641](#), [PMID:2539488](#), [PMID:2846394](#), [PMID:7972006](#), [PMID:8504475](#), [PMID:12894236](#), [PMID:15463957](#), [PMID:17331233](#), [PMID:20215515](#), [PMID:22521957](#), [PMID:25524072](#), [PMID:25877200](#), [PMID:31156620](#), [PMID:31900469](#)

Comments: Part of: Small cell lung cancer p53 hotspot mutation cell panel (ATCC TCP-2040)., Group: Patented cell line.

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: BEAS-2B

Synonyms: Beas-2B, BEAS 2B, BEAS2B, Beas2B, Bronchial Epithelium transformed with Ad12-SV40 2B

Cross References: BTO:BTO_0002923, CLO:CLO_0001925, EFO:EFO_0001089, MCCL:MCC:0000060, AddexBio:T0007001/26, ATCC:CRL-3588, ATCC:CRL-9609, BCRJ:0395, BioSample:SAMN03471073, BioSample:SAMN03472862, cancercellines:CVCL_0168, CCRID:3101HUMSCSP5067, CCRID:5301HUM-KCB09022YJ, CCTCC:GDC0139, ChEMBL-Cells:ChEMBL4295386, ChEMBL-Targets:ChEMBL4296403, CLS:300311, ECACC:95102433, GEO:GSE33520, GEO:GSM139654, GEO:GSM139655, GEO:GSM139656, GEO:GSM139657, GEO:GSM139659, GEO:GSM139660, GEO:GSM139661, GEO:GSM139663,

GEO:GSM139664, GEO:GSM139666, GEO:GSM171836, GEO:GSM171837, GEO:GSM253389, GEO:GSM827258, GEO:GSM3138797, GEO:GSM3138798, GEO:GSM3138799, GEO:GSM3138800, GEO:GSM3138801, GEO:GSM3138802, GEO:GSM3138803, GEO:GSM3138804, GEO:GSM3138805, Hysigen:TCH-C132, IARC_TP53:23556, KCB:KCB 200922YJ, Kerafast:ENH021-FP, Lonza:343, NCBI_Iran:C561, PRIDE:PXD003503, Progenetix:CVCL_0168, PubChem_Cell_line:CVCL_0168, Ubigen:YC-B005, Wikidata:Q54795940

ID: CVCL_0168

Vendor: Hysigen

Catalog Number: TCH-C132

Record Creation Time: 20260408T072617+0000

Record Last Update: 20260920T012617+0000

Ratings and Alerts

No rating or validation information has been found for BEAS-2B.

No alerts have been found for BEAS-2B.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3359 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Gao Y, et al. (2026) AMT inhibits the progression of non-small cell lung cancer by suppressing the PI3K/AKT/GSK-3 β -catenin pathway via H3K27me3 regulation. European journal of pharmacology, 1011, 178460.

Chen C, et al. (2026) Targeting STAT3 by SH-4-54 suppresses the occurrence and inactivates oxidative phosphorylation in small-cell lung cancer via the SRC signaling. Naunyn-Schmiedeberg's archives of pharmacology, 399(7), 9551.

Zhang SJ, et al. (2026) New Diketopiperazine Alkaloids From the Tuber of Pinellia Ternata (Thunb.) Breit. Chemistry & biodiversity, 23(4), e71206.

Yang K, et al. (2026) Rhein inhibits respiratory syncytial virus entry by stabilizing the prefusion conformation of the fusion protein. Journal of advanced research.

Dai Y, et al. (2026) Development and preclinical evaluation of KDTV001, an adenovirus 5-vectored trivalent HPV therapeutic vaccine targeting HPV16/18/52. EBioMedicine, 126,

106230.

Wang D, et al. (2026) UV-Activated Zwitterionic Fluorine-Containing Hybrid Probe for Dual-Modal 19F/1H MRI. *Biomacromolecules*, 27(4), 2938.

Pan W, et al. (2026) OTUD6A in Airway Epithelial Cells Exacerbates Allergic Asthma by Promoting Airway Inflammation and Airway Remodeling Through Deubiquitination of hResistin/mRELM?. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(18), e16355.

Feng X, et al. (2026) FOSL2-induced transcriptional activation of L1CAM promotes progression of lung adenocarcinoma via the PI3K/AKT/mTOR signaling pathway. *International immunopharmacology*, 168(Pt 1), 115810.

Zhao Y, et al. (2026) TOP2A, BUB1B, CENPF, KIF15 and MELK: Key senescence-related genes linked to prognosis and immune infiltration in lung adenocarcinoma. *International journal of biological macromolecules*, 335(Pt 1), 149215.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Pan Y, et al. (2026) A covalent molecular glue hijacks the E3 ligase MKRN2 to degrade the ribosomal protein RPS7 and induce synthetic lethality in p53-deficient NSCLC cells. *British journal of pharmacology*.

Li D, et al. (2026) The pivotal regulatory factor circ_0006956 promotes arsenic-induced lung carcinogenesis by enhancing the Warburg effect. *Chemico-biological interactions*, 435, 112170.

Feng R, et al. (2026) Veratramine alleviates asthmatic airway remodelling via the PKM2/CREB1 lactylation/SMAD7 axis. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 159, 158542.

Li J, et al. (2026) Lactylation Enhances the Activity of Lactate Dehydrogenase A and Promotes the Chemoresistance to Cisplatin Through Facilitating DNA Nonhomologous End Junction in Lung Adenocarcinoma. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(3), e10733.

Pan K, et al. (2026) Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy. *Biochemical pharmacology*, 243(Pt 2), 117562.

Weinberg F, et al. (2026) Integrative Analysis of Multiomic Pathways Predicts Cancer-Affected Lobes in Lung Cancer. *Cancer prevention research (Philadelphia, Pa.)*, 19(4), 229.

Chen Q, et al. (2026) FOXA1-mediated CEPT1 deficiency in airway epithelium drives asthma via an ER stress-mitochondrial dysfunction axis. *Cell reports*, 45(6), 117368.

Pantazaka E, et al. (2026) Repurposing Artesunate to Combat Progression and Metastasis via Targeting Circulating Tumor Cells. *Oncology research*, 34(6), 13.

Izzo LT, et al. (2026) KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma. *Cancer research*.

Wang F, et al. (2026) Extracellular vesicles derived from cancer-associated fibroblasts facilitate NSCLC progression and metastasis via miR-664b-5p-mediated activation of the CXCL12/CXCR4 chemokine pathway. *Biochimica et biophysica acta. Molecular basis of disease*, 1872(8), 168360.